Improved Clone Evaluation and Selection of CHO Cell Lines using ambr15®

8th August 2017

Category: Cell Line Development

Tags:

By: Anton Stefan - Scientist, Dirk Mueller - Team Leader, Dr Christoph Zehe - Lead Scientist, Michael Grauf - Scientist,

The global market for biopharmaceutical products continues to expand, making it a highly attractive market for biopharmaceutical companies. Due to the rising number of projects with variant protein drug candidate molecules, increasing productivity of cell culture process development to support material production for early phase clinical trials has been an important task in recent years. More

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy